CPT Code Overview

CPT code 78816 represents a whole body positron emission tomography (PET) scan with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization imaging. This procedure is classified under diagnostic nuclear medicine procedures (PET/CT whole body) and is typically performed in an outpatient hospital setting (POS 22). The combined PET/CT imaging provides comprehensive diagnostic information by integrating metabolic and anatomical data, supporting clinical decision-making in complex cases such as oncology, cardiology, and neurology.

Clinical Context

A typical patient scenario involves an adult presenting to an outpatient hospital setting for evaluation of a suspected or known malignancy. The patient may have a diagnosis such as lung cancer, breast cancer, prostate cancer, colon cancer, or pancreatic cancer. The ordering physician requests a whole body positron emission tomography (PET) scan with concurrently acquired computed tomography (CT) for attenuation correction and anatomical localization. This imaging procedure assists in initial staging or follow-up assessment of cancer, guiding treatment strategy and monitoring disease progression or response to therapy. The workflow includes patient preparation, radiotracer administration, imaging acquisition, and interpretation by a radiologist or nuclear medicine physician.

Coding Specifications

• Modifiers:

  • Modifier PI: Oncologic indications – initial treatment strategy (initial staging). Used when the PET/CT is performed for the first evaluation of a cancer diagnosis.

  • Modifier PS: Oncologic indications – subsequent treatment strategy (follow-up). Used when the PET/CT is performed for monitoring after initial treatment or for ongoing management.

• Provider Taxonomies:

  Taxonomy Code	Specialty Name
  2085R0202X	Radiology, Diagnostic Radiology
  2085N0700X	Radiology, Nuclear Radiology
  207U00000X	Nuclear Medicine Physician

These taxonomies represent providers specializing in diagnostic radiology, nuclear radiology, and nuclear medicine, who are qualified to interpret PET/CT imaging studies.

Related Diagnoses

• C34.90: Malignant neoplasm of unspecified part of unspecified bronchus or lung

  • Relevant for patients undergoing PET/CT for evaluation, staging, or follow-up of lung cancer.

• C50.919: Malignant neoplasm of unspecified site of unspecified female breast

  • Used for breast cancer patients requiring whole body PET/CT for staging or monitoring.

• C61: Malignant neoplasm of prostate

  • Indicates prostate cancer, where PET/CT may be used to assess metastatic disease or treatment response.

• C18.9: Malignant neoplasm of colon, unspecified

  • Applied for colon cancer cases, supporting whole body imaging for staging or surveillance.

• C25.9: Malignant neoplasm of pancreas, unspecified

  • Used for pancreatic cancer patients, assisting in comprehensive disease assessment with PET/CT.

Each diagnosis code represents a malignancy commonly evaluated with whole body PET/CT imaging for staging, treatment planning, or follow-up.

Related CPT Codes

• 78815: Positron emission tomography (PET) with concurrently acquired CT for attenuation correction and anatomical localization imaging; limited area (skull base to mid‑thigh)

  • Used when imaging is limited to a specific region rather than the whole body. May be selected based on clinical indication or payor requirements.

• 78811-78813: PET imaging without concurrent CT (various body regions)

  • These codes represent PET imaging performed without the CT component. They are alternatives when CT is not required for attenuation correction or anatomical localization.

In clinical workflow, 78816 is used for whole body PET/CT, while 78815 is used for limited area imaging. 78811-78813 are used when only PET imaging is performed, without concurrent CT. Selection depends on clinical need and payor guidelines. These codes are not typically billed together for the same session.

National mean rates for CPT code 78816 show a significant gap between Medicare and commercial payers. The average commercial rate, represented by BUCA, is $1,101.44, while Medicare's mean rate is $114.05. UnitedHealth Group has the highest mean rate at $1,531.86, and Blue Cross Blue Shield also exceeds $1,200.

Rate dispersion varies notably across payers. Cigna exhibits the widest spread, with a difference of $649.09 between its 75th and 25th percentiles, indicating substantial variability in contracted rates. In contrast, Medicare's range is only $6.00, reflecting highly standardized reimbursement. UnitedHealth Group and Blue Cross Blue Shield also show broad ranges, while Aetna and BUCA are somewhat tighter. The table and chart below present the full breakdown of national benchmarks for this code.